Timo Mäkikallio, Maina P. Jalava, Annastiina Husso, Marko Virtanen, Teemu Laakso, Tuomas Ahvenvaara, Tuomas Tauriainen, Pasi Maaranen, Eeva-Maija Kinnunen, Sebastian Dahlbacka, Jussi Jaakkola, Juhani Airaksinen, Vesa Anttila, Mikko Savontaus, Mika Laine, Tatu Juvonen, Antti Valtola, Peter Raivio, Markku Eskola, Matti Niemelä & Fausto Biancari (2019) Ten-year experience with transcatheter and surgical aortic valve replacement in Finland, Annals of Medicine, 51:3-4, 270-279, DOI: 10.1080/07853890.2019.1614657
Ten-year experience with transcatheter and surgical aortic valve replacement in Finland
|Author:||Mäkikallio, Timo1; Jalava, Maina P.2; Husso, Annastiina3;|
1Department of Internal Medicine, Oulu University Hospital, Oulu, Finland
2Heart Center, Turku University Hospital and University of Turku, Turku, Finland
3Heart Center, Kuopio University Hospital, Kuopio, Finland
4Heart Hospital, Tampere University Hospital, Tampere, Finland
5Heart Center, Helsinki University Hospital, Helsinki, Finland
6Department of Surgery, Oulu University Hospital and University of Oulu, Finland
7Department of Surgery, University of Turku, Turku, Finland
|Online Access:||PDF Full Text (PDF, 2.6 MB)|
|Persistent link:|| http://urn.fi/urn:nbn:fi-fe202002185666
|Publish Date:|| 2020-02-18
Aim: We investigated the outcomes of transcatheter (TAVR) and surgical aortic valve replacement (SAVR) in Finland during the last decade.
Methods: The nationwide FinnValve registry included data from 6463 patients who underwent TAVR or SAVR with a bioprosthesis for aortic stenosis from 2008 to 2017.
Results: The annual number of treated patients increased three-fold during the study period. Thirty-day mortality declined from 4.8% to 1.2% for TAVR (p = 0.011) and from 4.1% to 1.8% for SAVR (p = 0.048). Two-year survival improved from 71.4% to 83.9% for TAVR (p < 0.001) and from 87.2% to 91.6% for SAVR (p = 0.006). During the study period, a significant reduction in moderate-to-severe paravalvular regurgitation was observed among TAVR patients and a reduction of the rate of acute kidney injury was observed among both SAVR and TAVR patients. Similarly, the rate of red blood cell transfusion and severe bleeding decreased significantly among SAVR and TAVR patients. Hospital stay declined from 10.4 ± 8.4 to 3.7 ± 3.4 days after TAVR (p < 0.001) and from 9.0 ± 5.9 to 7.8 ± 5.1 days after SAVR (p < 0.001).
Conclusions: In Finland, the introduction of TAVR has led to an increase in the invasive treatment of severe aortic stenosis, which was accompanied by improved early outcomes after both SAVR and TAVR.
Annals of medicine
|Pages:||270 - 279|
|Type of Publication:||
A1 Journal article – refereed
|Field of Science:||
3121 General medicine, internal medicine and other clinical medicine
© 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed,or built upon in any way.